Mary Frances McAleer,Dae W Kim,Van A Trinh et al.
Mary Frances McAleer et al.
Relapses in the brain remain a major obstacle to cure in many patients with advanced melanoma. At present, the management of melanoma brain metastases continues to rely heavily on surgical and radiotherapeutic interventions, which have beco...
Predicting the outcome of melanoma: can we tell the future of a patient's melanoma? [0.03%]
预测黑色素瘤的转归：我们可以预知患者的黑色素瘤的发展趋势吗？
Oriol Yélamos,Pedram Gerami
Oriol Yélamos
Cutaneous melanoma is responsible for the greatest number of skin cancer related deaths. For many years there were few therapeutic options. However, in the last years a number of new therapeutic options have emerged showing improved surviva...
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial [0.03%]
关于BRAF突变型黑色素瘤的治疗： vemurafenib与cobimetinib联合使用对抗安慰剂的CoBRIM试验结果
Antonio M Grimaldi,Ester Simeone,Paolo A Ascierto
Antonio M Grimaldi
The concomitant inhibition of both BRAF and MEK can produce a more durable and greater tumor response than BRAF monotherapy while reducing BRAF inhibitor-related toxicity. Further evidence of the benefits of combined MEK and BRAF inhibition...
Samantha Bowyer,Rebecca Lee,Alberto Fusi et al.
Samantha Bowyer et al.
Approximately 50% of melanomas have mutations in the gene encoding BRAF. In recent years, new targeted therapies have transformed the landscape of metastatic melanoma treatment. Dabrafenib, a potent kinase inhibitor of mutated BRAF, has bee...
From personalized to patient-specific treatment of metastatic melanoma [0.03%]
从个性化治疗到针对黑色素瘤患者的个体化治疗
Robert O Dillman
Robert O Dillman
Graham G Walmsley,Michael S Hu,Zeshaan N Maan et al.
Graham G Walmsley et al.
Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management [0.03%]
恶性雀斑样黑色素瘤的诊断和治疗的当代问题
Karen L Connolly,Kishwer S Nehal,Klaus J Busam
Karen L Connolly
Lentigo maligna and lentigo maligna melanomas present diagnostic and treatment dilemmas due to their frequent presence within a background of sun-damaged skin, and their location on cosmetically and functionally sensitive areas. As the inci...
Dimitrios Papakostas,Irene Stefanaki,Alexander Stratigos
Dimitrios Papakostas
Germline CDKN2A mutations were the first to be associated with familial melanoma. MC1R polymorphisms are associated, in conformity with epidemiological observations, with fair skin phenotype and a moderately increased risk for melanoma. The...
Epidemiological and genetic factors underlying melanoma development in Italy [0.03%]
意大利黑色素瘤发病的流行病学和遗传因素
Giuseppe Palmieri,Maria Colombino,Milena Casula et al.
Giuseppe Palmieri et al.
Among human cancers, melanoma remains one of the malignancies with an ever-growing incidence in white populations. Recent advances in biological and immunological therapeutic approaches as well as increased efforts for secondary prevention ...
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma [0.03%]
用于治疗皮肤黑色素瘤的致癌基因导向的小分子抑制剂
Philip Eliades,Keith T Flaherty,Hensin Tsao
Philip Eliades
Achievements in cancer genetics and molecular biology have revolutionized the treatment options available for advanced melanoma. Patients with certain molecularly defined melanomas have been the most fortunate beneficiaries of recently US F...